<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064439</url>
  </required_header>
  <id_info>
    <org_study_id>16416</org_study_id>
    <secondary_id>2013-000619-26</secondary_id>
    <nct_id>NCT02064439</nct_id>
  </id_info>
  <brief_title>Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)</brief_title>
  <acronym>EinsteinChoice</acronym>
  <official_title>Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, event-driven, superiority study for
      efficacy.

      Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who
      completed 6 or 12 months of treatment of anticoagulation are eligible for this trial
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2014</start_date>
  <completion_date type="Actual">November 4, 2016</completion_date>
  <primary_completion_date type="Actual">September 22, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism</measure>
    <time_frame>Up to 12 months, at least 6 months</time_frame>
    <description>The primary efficacy outcomes (i.e., recurrent venous thromboembolism [VTE] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism [PE] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment.
Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With First Treatment-emergent Major Bleeding</measure>
    <time_frame>Up to 12 months, at least 6 months</time_frame>
    <description>The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death.
Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Composite of the Primary Efficacy Outcome, Myocardial Infarction, Ischemic Stroke or Systemic Non-CNS Embolism</measure>
    <time_frame>Up to 12 months, at least 6 months</time_frame>
    <description>The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-major Bleeding Associated With Study Drug Interruption for &gt; 14 Days</measure>
    <time_frame>Up to 12 months, at least 6 months</time_frame>
    <description>The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3365</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Thromboembolism</condition>
  <condition>Thrombosis</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 10 mg once daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 20 mg once daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 59-7939</intervention_name>
    <description>10 mg tablet once daily for 12 months</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 59-7939</intervention_name>
    <description>20 mg tablet once daily for 12 months</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>100 mg tablet once daily for 12 months</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed symptomatic PE and/or DVT who have been treated for 6 to 12
             months and did not interrupt anticoagulation for longer than 1 week

        Exclusion Criteria:

          -  Legal lower age limitations (country specific) Indication for therapeutic-dosed
             anticoagulants Indication for antiplatelet therapy or a conventional non-steroid
             anti-inflammatory drug (NSAID) Hepatic disease which is associated with coagulopathy
             leading to a clinically relevant bleeding risk Calculated creatinine clearance &lt; 30
             mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockport</city>
        <state>Maine</state>
        <zip>04856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405-2433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redcliffe</city>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>09190-615</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01323-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>04039-004</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shengyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kladno</city>
        <zip>27259</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liberec</city>
        <zip>46063</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Litomysl</city>
        <zip>570 14</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>728 80</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <zip>118 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 1</city>
        <zip>110 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Svendborg</city>
        <zip>5700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bois-guillaume</city>
        <zip>76320</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>BREST Cedex 9</city>
        <zip>29240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Castelnau Le Lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colombes Cedex</city>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Kremlin Bicetre Cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vernon</city>
        <zip>27200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Witten</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58448</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlsbad</city>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <zip>5810001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <zip>2210001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zefat</city>
        <zip>1311001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chieti</city>
        <state>Abruzzo</state>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cosenza</city>
        <state>Calabria</state>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piacenza</city>
        <state>Emilia-Romagna</state>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varese</city>
        <state>Lombardia</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Treviso</city>
        <state>Veneto</state>
        <zip>31029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Treviso</city>
        <state>Veneto</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donggu,</city>
        <state>Gwangju Gwang''yeogsi</state>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>León</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64718</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xalapa</city>
        <state>Veracruz</state>
        <zip>91020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <state>Yucatán</state>
        <zip>97129</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <zip>31203</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almere</city>
        <zip>1315 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Assen</city>
        <zip>9401 RK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dordrecht</city>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sittard</city>
        <zip>6131 BK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>1309</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>2024</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palmerston North</city>
        <zip>4414</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fredrikstad</city>
        <zip>1603</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quezon City</city>
        <zip>NCR 1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-631</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tver</city>
        <zip>170036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2132</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2191</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria West</city>
        <state>Gauteng</state>
        <zip>0082</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roodepoort</city>
        <state>Gauteng</state>
        <zip>1724</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kristianstad</city>
        <zip>29185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fribourg</city>
        <zip>1700</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Taipei City</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34-300</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34760</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hull</city>
        <state>Humberside</state>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ha Noi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ho Chi Minh</city>
        <zip>70000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <reference>
    <citation>Weitz JI, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Holberg G, Kakkar A, Lensing AW, Prins M, Haskell L, van Bellen B, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost. 2015 Aug 31;114(3):645-50. doi: 10.1160/TH15-02-0131. Epub 2015 May 21.</citation>
    <PMID>25994838</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <results_first_submitted>September 12, 2017</results_first_submitted>
  <results_first_submitted_qc>December 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2017</results_first_posted>
  <last_update_submitted>December 17, 2017</last_update_submitted>
  <last_update_submitted_qc>December 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep vein thrombosis</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>long-term prevention of recurrent symptomatic VTE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In total 3439 participants were screened at 244 sites in 31 countries from 05-Mar-2014 (First Patient First Visit) to 15-Mar-2016 (Last Patient First Visit).</recruitment_details>
      <pre_assignment_details>Of the 3439 participants screened 43 did not complete screening. Thus, 3396 participants were randomly assigned to treatment, 31 of the randomized participants never received study medication because either withdrew consent or were withdrawn from the study based on protocol violations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD</title>
          <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 10 mg tablet or matching placebo once daily (OD) with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
        </group>
        <group group_id="P2">
          <title>Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD</title>
          <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 20 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
        </group>
        <group group_id="P3">
          <title>Acetylsalicylic (ASA) 100 mg, OD</title>
          <description>Participants were randomized, stratified by country and by index event, to receive ASA 100 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1127">Full Analysis Set (FAS), randomized and received study medication</participants>
                <participants group_id="P2" count="1107">FAS, randomized and received study medication</participants>
                <participants group_id="P3" count="1131">FAS, randomized and received study medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="984"/>
                <participants group_id="P2" count="969"/>
                <participants group_id="P3" count="949"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="182"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study medication</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Logistical difficulties</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Efficacy outcome reached</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety outcome reached</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD</title>
          <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 10 mg tablet or matching placebo once daily (OD) with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
        </group>
        <group group_id="B2">
          <title>Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD</title>
          <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 20 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
        </group>
        <group group_id="B3">
          <title>Acetylsalicylic (ASA) 100 mg, OD</title>
          <description>Participants were randomized, stratified by country and by index event, to receive ASA 100 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1127"/>
            <count group_id="B2" value="1107"/>
            <count group_id="B3" value="1131"/>
            <count group_id="B4" value="3365"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="14.7"/>
                    <measurement group_id="B2" value="57.9" spread="14.7"/>
                    <measurement group_id="B3" value="58.8" spread="14.7"/>
                    <measurement group_id="B4" value="58.5" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="507"/>
                    <measurement group_id="B2" value="505"/>
                    <measurement group_id="B3" value="488"/>
                    <measurement group_id="B4" value="1500"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="620"/>
                    <measurement group_id="B2" value="602"/>
                    <measurement group_id="B3" value="643"/>
                    <measurement group_id="B4" value="1865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="892"/>
                    <measurement group_id="B2" value="899"/>
                    <measurement group_id="B3" value="889"/>
                    <measurement group_id="B4" value="2680"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="479"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="786"/>
                    <measurement group_id="B2" value="772"/>
                    <measurement group_id="B3" value="786"/>
                    <measurement group_id="B4" value="2344"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism</title>
        <description>The primary efficacy outcomes (i.e., recurrent venous thromboembolism [VTE] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism [PE] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment.
Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.</description>
        <time_frame>Up to 12 months, at least 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 10 mg tablet or matching placebo once daily (OD) with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 20 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
          <group group_id="O3">
            <title>Acetylsalicylic (ASA) 100 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive ASA 100 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism</title>
          <description>The primary efficacy outcomes (i.e., recurrent venous thromboembolism [VTE] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism [PE] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment.
Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1127"/>
                <count group_id="O2" value="1107"/>
                <count group_id="O3" value="1131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic recurrent Deep vein thrombosis (DVT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic recurrent PE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (PE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (unexplained and PE cannot be ruled out)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the first occurrence of the composite outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the first occurrence of the composite outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the first occurrence of the composite outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4328</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Treatment-emergent Major Bleeding</title>
        <description>The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death.
Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.</description>
        <time_frame>Up to 12 months, at least 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 10 mg tablet or matching placebo once daily (OD) with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 20 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
          <group group_id="O3">
            <title>Acetylsalicylic (ASA) 100 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive ASA 100 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Treatment-emergent Major Bleeding</title>
          <description>The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death.
Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1127"/>
                <count group_id="O2" value="1107"/>
                <count group_id="O3" value="1131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any major bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-fatal critical organ bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-fatal non-critical organ bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the first occurrence of the composite outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3235</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>8.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the first occurrence of the composite outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5005</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>6.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the first occurrence of the composite outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7337</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>4.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Composite of the Primary Efficacy Outcome, Myocardial Infarction, Ischemic Stroke or Systemic Non-CNS Embolism</title>
        <description>The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.</description>
        <time_frame>Up to 12 months, at least 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 10 mg tablet or matching placebo once daily (OD) with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 20 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
          <group group_id="O3">
            <title>Acetylsalicylic (ASA) 100 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive ASA 100 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Composite of the Primary Efficacy Outcome, Myocardial Infarction, Ischemic Stroke or Systemic Non-CNS Embolism</title>
          <description>The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1127"/>
                <count group_id="O2" value="1107"/>
                <count group_id="O3" value="1131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ischemic stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-CNS systemic embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic recurrent DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic recurrent PE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (PE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (unexplained and PE cannot be ruled out)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (cardiovascular: myocardial infarction)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (cardiovascular: ischemic stroke)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the first occurrence of the composite outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the first occurrence of the composite outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis was performed on the first occurrence of the composite outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8172</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-major Bleeding Associated With Study Drug Interruption for &gt; 14 Days</title>
        <description>The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days.</description>
        <time_frame>Up to 12 months, at least 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 10 mg tablet or matching placebo once daily (OD) with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 20 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
          <group group_id="O3">
            <title>Acetylsalicylic (ASA) 100 mg, OD</title>
            <description>Participants were randomized, stratified by country and by index event, to receive ASA 100 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-major Bleeding Associated With Study Drug Interruption for &gt; 14 Days</title>
          <description>The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1127"/>
                <count group_id="O2" value="1107"/>
                <count group_id="O3" value="1131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3318</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>3.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9726</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>2.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3137</p_value>
            <p_value_desc>P-value and hazard ratio estimates based on stratified proportional hazards model, with stratification based index event (DVT or PE with or without DVT).</p_value_desc>
            <method>Wald test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From after start of study medication but not more than 2 days after stop of study medication.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD</title>
          <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 10 mg tablet or matching placebo once daily (OD) with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
        </group>
        <group group_id="E2">
          <title>Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD</title>
          <description>Participants were randomized, stratified by country and by index event, to receive rivaroxaban 20 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
        </group>
        <group group_id="E3">
          <title>Acetylsalicylic (ASA) 100 mg, OD</title>
          <description>Participants were randomized, stratified by country and by index event, to receive ASA 100 mg tablet or matching placebo OD with food for 12, or 9 to less than 12, or 6 months depending on the date of randomization. Treatment of all participants stopped 6 months after the last participant was randomized.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="1127"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="1107"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushing's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Hypertrophic anal papilla</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Eosinophilic oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Colon dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Overlap syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Plasmodium falciparum infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="1107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Urethral abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Stomal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cystoscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>B-lymphocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint ankylosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Benign gastric neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Rectal cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cervix warts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Malignant glioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Ovarian cancer stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Axonal neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Meningioma surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.3</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1127"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1107"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1107"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1127"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1107"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1107"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1107"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1127"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="1107"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1107"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1107"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1131"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The steering committee will be responsible for the publication and presentation strategy. All publications will be based on data released or agreed by Bayer, verified by the steering committee.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Bayer AG</organization>
      <email>clinical-trials-contact@bayer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

